Intravenous immunoglobulin (IVIg) has been shown to be eŠective for a variety of autoimmune diseases. Despite its widespread use and therapeutic success, the precise mechanisms for the anti-in‰ammatory therapeutic eŠects of IVIg are not well understood. In particular, few reports have examined the mechanism of IVIg on regulatory T cells (Treg:
. S-IVIg in a dose range of 0 800 mg/kg body weight was intraperitoneally administrated for 5 days from day 0 of immunization. The severity of the disease was evaluated daily using a clinical score as explained in``Methods 2''. Each data point represents the mean plus or minus S.E. of clinical scores (n＝12). S-IVIg administration (100 800 mg/kg) suppresses all the clinical parameters (date of onset, duration, the maximal score, AUC) in EAE mice. The Shirley-Williams test was used for statistical analysis ( p＜0.05).
Fig. 2. Histological Analysis of the Cervical Spinal Cord of EAE Mice Stained with Luxol Fast Blue-haematoxylin/eosin
Histological examination of saline-treated (left) and S-IVIg-treated (right) mice were performed using spinal cord tissues taken on day 21. Saline-treated mice showed lymphocytic inˆltration and marked demyelination while S-IVIg-treated did not. EAE mice were sacriˆced on day 17 after immunization. CD4 ＋ cells were isolated from spleen cells with magnetic beads and cultured in RPMI1640 medium supplemented with 5％ FBS. After the addition of 1 mL/mL Golgi Stop to prevent cytokine secretion, the cells were incubated for 6 h and stained for accumulated cytokines using appropriate ‰uores-cently labeled antibodies by ‰ow cytometry. Each data point represents the mean plus or minus S.D. (n＝3). The percentage of IL-10 and TGF-b producing cells in S-IVIg-treated mice was signiˆcantly high compared with Saline-treated mice. A paired t-test was used to calibrate diŠerences between the paired mean values ( p＜0.05). 
. Suppression of Clinical Symptoms of Reinduction of EAE by S-IVIg
Reinduction of EAE was performed on day 42 after primary immunization. IVIg at a dose of 800 mg/kg body weight was intraperitoneally administrated for 5 days from day 42 of reimmunization. The severity of the disease was evaluated daily using a clinical score as explained in``Methods 2''. Each data point represents the means plus or minus S.E. of clinical scores (n＝12). IVIg administration suppresses the clinical score (the maximal score and AUC) in EAE mice. The MannWhitney U test was used for statistical analysis ( p＜0.05). 
